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ARTICLE
Supramolecular aptamer nano-constructs for
receptor-mediated targeting and light-triggered
release of chemotherapeutics into cancer cells
Deepak K. Prusty1,2, Volker Adam1, Reza M. Zadegan 3, Stephan Irsen4 & Michael Famulok 1,2
Platforms for targeted drug-delivery must simultaneously exhibit serum stability, efficient
directed cell internalization, and triggered drug release. Here, using lipid-mediated self-
assembly of aptamers, we combine multiple structural motifs into a single nanoconstruct that
targets hepatocyte growth factor receptor (cMet). The nanocarrier consists of lipidated
versions of a cMet-binding aptamer and a separate lipidated GC-rich DNA hairpin motif
loaded with intercalated doxorubicin. Multiple 2′,6′-dimethylazobenzene moieties are
incorporated into the doxorubicin-binding motif to trigger the release of the chemother-
apeutics by photoisomerization. The lipidated DNA scaffolds self-assemble into spherical
hybrid-nanoconstructs that specifically bind cMet. The combined features of the nanocarriers
increase serum nuclease resistance, favor their import into cells presumably mediated by
endocytosis, and allow selective photo-release of the chemotherapeutic into the targeted
cells. cMet-expressing H1838 tumor cells specifically internalize drug-loaded nanoconstructs,
and subsequent UV exposure enhances cell mortality. This modular approach thus paves the
way for novel classes of powerful aptamer-based therapeutics.
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There is a compelling demand for improvements in theeffectiveness in both the transport and specific release oftherapeutic molecules. A powerful approach is the use of
aptamer-based tumor targeting systems1–5 in combination with
controlled release of active therapeutics through physico-chemical
responses to external stimuli such as pH6–9, light10–12, and che-
micals13–15, or internal cell markers16,17. Due to their advantages
over other targeting reagents such as easy synthesis, low immu-
nogenicity, and high target affinity, DNA aptamers have opened
up new opportunities for cellular targeting and have been selected
against various cancer types, including prostate18–20, pancrea-
tic21,22, colon23,24, and breast cancer25–27. However, aptameric
molecular nanocarriers are often limited by inefficient cellular
uptake and short intracellular half-life as they are naturally sus-
ceptible to nuclease-mediated degradation.
Progress has been made to improve serum half-life and cell
internalization efficacy by functionalizing nanocarriers with
aptamers that target specific surface proteins, for instance poly-
meric nanoparticles28,29, liposomes30–33, aptamer-drug con-
jugates34–36, aptamer-antibody conjugates37,38, and aptamer-
functionalized quantum dots39–41. However, the majority of
these approaches entailed significant trade-offs between compli-
cated assembly, suboptimal size, limited payload capacity, and
some show insufficient serum stability and cell internalization
efficacy. In the case of aptamer-drug conjugates, covalent linking
of targeting units to cytotoxic agents is one possibility for efficient
treatment; however, in some cases limited by the concern that the
attachment may alter their biological activity. Several recent
studies employed a native cell-targeting aptamer that was mod-
ified by additional nucleobases for drug intercalation as a dual
factor for cell targeting and, simultaneously, as a cargo for drug
transport42–44. Yet, there is an inherent limitation to broader
applicability for such architectures: especially when extended to
other aptameric platforms for targeting different cell types, even a
minor modification of the aptamer sequence with a drug loading
unit might result in significant disruption of binding affinity.
An alternative and highly versatile approach to minimize these
drawbacks is to incorporate a cell-targeting aptamer unit and
separate drug-carrying functionalities into a single multi-
functional nano-assembly. These units can be anchored onto a
single nanoscaffold through non-covalent interactions, enabling
convenient self-assembly of tunable modular components. The
advantage of such a system is that simple mixing of the two, or
more, moieties would spontaneously self-assemble into a single
nanoconstruct containing these motifs. A possible strategy to
explore this concept would be harnessing the lipid-based self-
assembly of two lipidated structures, one for cell-targeting, the
other for drug loading. Potentially suitable candidate cell-
targeting moieties are DNA aptamers that bind to extracellular
domains of transmembrane receptors, an example being the DNA
aptamer cln00345, which binds with high specificity and affinity
to the transmembrane receptor “hepatocyte growth factor
receptor” HGFR (also called cMet)46. cMet is expressed on the
surface of numerous solid tumors.
The DNA-intercalating drug doxorubicin (DxR) is one of the
most potent and widely used chemotherapeutics, but its lack of
specificity induces adverse side effects and toxicities. Substantial
efforts in transforming the use of free DxR into targeted DxR-
carrier systems were undertaken47–49, but a common limitation is
inefficient drug release. Designing multi-functional nano-
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Fig. 1 Assembly and characterization of the photo-switchable aptameric nanoconstruct. a Structures of the lipid-functionalized dU-phosphoramidite 1, the
2′,6′-dimethylazobenzene-D-threoninol residue 2, and doxorubicin DxR. b The lipid-functionalized anti-cMet aptamer trCLN3-L4 3 and its self-assembly
into the corresponding trCLN3-L4 nanoconstruct. c AFM images of the trCLN3-L4 3 nanoconstruct shows its size and morphology. Scale bar: 200 nm. d
Size distribution of the trCLN3-L4 3 nanoconstructs. e The lipid-functionalized DxR-carrier hairpin motif DxR-L4 4modified with 2′,6′-dimethylazobenzene
2 (purple), and the self-assembly of 3, 4, and DxR (blue) to form DxR-loaded HyApNc-DxR nanoconstruct. f AFM images of the HyApNc-DxR
nanoconstruct shows its size and morphology. Scale bar: 200 nm. g Size distribution of the HyApNc-DxR nanoconstructs. The size distributions in d and g
show that the hybrid nanoconstructs HyApNc-DxR are on average about 10 nm larger than the homogeneous trCLN3-L4 nanoconstructs
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constructs as delivery vehicles without an efficient release
mechanism will probably limit the development of a potent drug
delivery platform. The often-used antisense-strategy50,51 is both
highly complex and polluting, due to the resulting ODN “waste”
strands, hence limited as an efficient release system. In contrast,
light is an excellent tool for both actively and remotely controlling
the release of biologically active caged compounds52,53. Sys-
tematic investigation of light for cytotoxic drug release is scarce,
though it promises simple active control with minimal waste
accumulation and is well suited for ODN-based carrier systems.
Photoresponsive azobenzene derivatives have been incorporated
into ODN-backbones to reversibly open and close ODN-duplexes
upon light irradiation54,55. Such light-responsive systems can
control cellular56,57 and biological activities like regulation of
gene expression58 or reversible tuning of DNA nanoarchi-
tectures59–61. However, studies that systematically explore the
control of cytotoxic drug release from aptameric cages modified
with photo-responsive moieties inside the ODN-backbone are
scarce.
Here, we report the design of a versatile and broadly applicable
photo-switchable hybrid-aptameric nanoconstruct (HyApNc) as
an efficient molecular carrier that selectively targets and trans-
ports high doses of DxR directly into cMet-expressing cells and
releases the payload under light irradiation. Specifically, we use a
truncated, variant of cln003 comprising 40 nucleotides (trCLN3)
that binds to cMet with nanomolar affinity and was previously
used for aptamer-based affinity labeling of cMet in living cells62.
For the drug-carrying domain, a separate 5′-GC-rich hairpin
ODN motif was designed to intercalate and transport DxR. We
incorporate 2′,6′-dimethylazobenzene (DMAB) photoswitches
into the drug-carrying ODN domain, enabling controlled release
of DxR through UV irradiation. Our concept of a photo-
switchable HyApNc addresses key concerns for aptameric deliv-
ery platforms: specificity, stability, tuneability, and triggered
release. The exemplary system we introduce selectively targets
cMet-expressing cells with the aptamer trCLN3 and transports
high doses of DxR for release under irradiation. These active
components (both trCLN3 and DxR-binding motifs) are chemi-
cally modified with four C12-lipids (L4), enabling self-assembly
into rigid, multi-component supramolecular structures. The
aptamer-motif trCLN3-L4 (3) allows specific binding to cMet on
the cell surface, leading to internalization of the HyApNc, car-
rying DxR intercalated into the DxR-L4 motif. Photo-
isomerization of DMAB triggers de-hybridization of the double
helix and release of DxR. The design of the system allows using a
large variety of other types of lipid-modified aptamers or mole-
cules that all can, in principle, self-assemble into a single func-
tional nanoconstruct so that a highly versatile applicability of this
platform becomes possible.
Results
Assembly of anti-cMet trCLN3-L4 nanoconstructs. As a proof
of concept, we used the 40-nucleotide anti-cMet DNA aptamer
trCLN3 that binds to HGFR (cMet) with a dissociation constant
(Kd) of 38 nM62. cMet is expressed on the surface of several types
of cancer cells, including the NCI-H1838 lung cancer cell line
used here63,64. In a first step (Fig. 1), we synthesized the lipid-
modified phosphoramidite 1 with a C12-lipid chain incorporated
at the 5-position of the uridine base (Fig. 1a; Supplementary
Figs. 1, 2). Four of these modified bases were attached to the 5′-
end of the trCLN3 aptamer (Fig. 1b; Supplementary Fig. 3),
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Fig. 2 Serum stability of trCLN3 aptamer and its lipid-functionalized derivatives. a, b PAGE-analysis of the degradation pattern of aptamer trCLN3, trCLN3.
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thereby introducing four lipid tails into each aptamer. The
resulting lipid-functionalized aptamer trCLN3-L4 (3) was pur-
ified by reversed-phase HPLC (Supplementary Fig. 4) and con-
firmed by LCMS mass spectrometry (Supplementary Fig. 5).
Polyacrylamide gel electrophoresis (PAGE) of lipidated and non-
lipidated trCLN3 aptamers showed significant differences in the
migration behavior, consistent with L4-modification (data not
shown). Moreover, the L4-modified aptamers showed a strong
tendency to self-aggregate in aqueous solution by forming sphe-
rical nanoconstructs above a critical micelle concentration (CMC)
at room temperature. We evaluated the CMC of the trCLN3-L4
nanoconstructs using Förster resonance energy transfer (FRET;
Supplementary Methods; Supplementary Fig. 6; Supplementary
Table 1)65,66 and fluorescence studies with pyrene-loaded
trCLN3-L4 nanoconstructs (Supplementary Fig. 7; Supplemen-
tary Table 2)67. Both methods yielded CMC values in the range of
300–350 nM concentrations. The size and morphology of the
nanoconstructs were further studied by atomic force microscopy
(AFM; Fig. 1c) and electron microscopy (TEM; Supplementary
Fig. 8). To obtain a statistical evaluation of the size distribution of
nanoconstructs, the diameters of at least 50 nanoconstructs for
each AFM image were compiled in histograms and fitted by
Gaussian distributions (Fig. 1d). The trCLN3-L4 3 nanocon-
structs have an average diameter of 21.2± 1.5 nm (Fig. 1d),
consistent with the size of 25 nm measured by TEM.
Effect of lipid modifications on cMet binding and serum
nuclease stability. To test the influence of lipid tails on aptamer
binding, a competitive filter-binding assay was carried out.
Varying concentrations of unlabeled 5′-lipid-functionalized
aptamer 3 and its two-point mutant variant trCLN3.mut-L4
(Supplementary Methods) competed with a constant amount of
32P-labeled native trCLN3 aptamer in binding to cMet. Strong
cMet binding was observed for trCLN3-L4 with an IC50 value of
43 nM, compared to 56 nM obtained for the non-lipidated native
aptamer trCLN3 (Supplementary Fig. 9). This result demonstrates
that aptameric nanoconstructs retained their binding affinity to
cMet as compared to the non-modified aptamer trCLN3. In
contrast, the lipidated mutant aptamer trCLN3.mut-L4 contain-
ing two point mutations could not compete with the 32P-trCLN3
for binding to cMet within the tested concentration range, indi-
cating that the displacement of the non-lipidated 32P-trCLN3
from its bound cMet-target by its lipidated counterpart trCLN3-
L4 is specific.
Since an adequate serum half-life is a prerequisite for the
successful in vivo application of these aptamers, the serum
stabilities of aptamer trCLN3, its double point mutant non-
binding variant trCLN3.mut, and their corresponding lipid-
functionalized derivatives (trCLN3-L4 and trCLN3.mut–L4,
respectively) were analyzed in 90% PBS-buffered fetal calf serum
(FCS) (Fig. 2a) and in freshly prepared human blood serum
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(HBS, Fig. 2b) at 37 °C from 0 to 72 h (full uncropped PAGE
included as Supplementary Figs. 10, 11). A comparison of
degradation profiles between FCS and HBS (Fig. 2c) revealed
fairly similar patterns of aptamer degradation for both serum
samples. The non-lipidated variants of the aptamer samples
degraded 1.5-fold faster in HBS compared to FCS. Under similar
conditions the serum half-life (t1/2) of trCLN3 was 8.7 h (90%
PBS-buffered FCS) and 4.9 h (90% PBS-buffered HBS), respec-
tively, compared to its lipid-functionalized derivative trCLN3-L4
showing no significant degradation even up to 72 h of incubation
in both sera. To exclude the possibility that the differences in
serum stability are due to the G-quadruplex present in both
trCLN3-L4 and trCLN3, we also compared serum stabilities of
trCLN3.mut-L4 and trCLN3.mut, both not capable of forming a
G-quadruplex. The t1/2 values of trCLN3.mut-L4 in FCS (~30.6 h)
and in HBS (~36.8 h), respectively, was approximately 10-fold
and 19-fold higher than that of the non-lipidated variant trCLN3.
mut (t1/2 = 2.8 h in FCS; 1.9 h in HBS). These observations clearly
indicate that the serum stability of the mutant aptamer is lower
than that of trCLN3 native aptamer, and lipidation further
protects the aptamer against enzymatic degradation thereby
increasing the serum stability several fold.
Design of a photoswitchable DxR-binding motif. We next
synthesized the thermodynamically stable lipid-modified DNA
motif 4 (Fig. 1e) consisting of a preferred DxR-binding 37
nucleotide alternating GC sequence combined with four DMAB
moieties and 4-lipid tails attached to the 5′-end (Fig. 3a, b). Motif
4 was designed to bind and release DxR reversibly by irradiating
with UV or visible light (Supplementary Methods) and the
integrity of the DxR-L4 motif 4 was confirmed by LC-MS
(Supplementary Fig. 12). Reversible photoswitching of the four
DMAB groups contained in motif 4 was investigated by UV/vis
spectroscopy. The switching process is fully reversible and can be
repeated for at least five irradiation cycles (Fig. 3c). This result is
further supported by gel electrophoresis of the DMAB-modified
GC-rich hairpin structure that showed a change in electro-
phoretic shift upon repeated irradiation with UV and visible light
for 5 min each (Fig. 3d; Supplementary Fig. 13), consistent with
significant structural changes between the hairpin and dehy-
bridized motif.
The goal of intercalating and efficiently delivering multiple
DxR molecules per motif 4 was investigated by binding studies
between motif 4 and DxR. A fixed concentration (10 µM) of DxR
was incubated with an increasing molar ratio of motif 4 (1–7 µM)
and fluorescence quenching due to intercalation of DxR was used
to examine the binding efficiency. Gradual decrease of the
fluorescence intensity of DxR was observed upon binding to
increasing amounts of motif 4 (Fig. 3e). We further tested the
difference in binding affinity of motif 4 for the cis- and trans-
conformations of the DMAB groups. To do so, motif 4 was
separately irradiated with visible light (λ = 450 nm) and UV light
(λ = 365 nm) for 5 min each and mixed with a fixed concentration
of DxR (10 µM), while the concentration of motif 4 was varied
from 0.1–0.7 equivalents to that of the DxR concentration. The
fluorescence curve of motif 4 with DMAB in trans-conformation
(λ = 450 nm) showed a higher reduction in fluorescence intensity
with an increasing molar equivalent of added motif 4 as
compared to 4 in which the DMAB moieties were in cis-
conformation. The difference in fluorescence intensity is about
30% higher in case of trans-DMAB than in cis-DMAB (Fig. 3f).
This difference in fluorescence intensities further supports the
conclusion, that the DMAB-modified motif 4 is destabilized by
irradiation with UV-light thereby releasing DxR.
Next, we evaluated the percentage of DxR bound to motif 4. A
fixed amount of motif 4 (5 µM) intercalated with a 10-fold excess
of DxR for 12 h followed by a purification step using spin
filtration (Supplementary Methods). After each centrifugation
step, a UV/vis spectrum of the flow through washing was
recorded. A 20% reduction in DxR absorbance confirmed that
approximately eight equivalents of DxR intercalate per motif 4,
and that two equivalents of excess DxR are removed through
repeated washing (Supplementary Fig. 14).
We then quantified the DxR release from the loaded DxR-L4
motifs under photoirradiation by an HPLC assay, detecting the
fluorescence of the remaining DxR bound to motif 4 after
removing unbound excess DxR from the solution. Phenol/CHCl3
(1:1) washing is known to remove unbound excess DxR in the
presence of DNA duplexes without removing the intercalated
DxR68. We then compared the amount of released DxR to that
observed by self-diffusion of DxR into the buffer medium
incubated at 37 °C over time (Supplementary Fig. 15a, b). After 5
min of UV irradiation (λ = 365 nm, 350 mW cm−2), an approxi-
mately 3-fold drop in fluorescence emission was observed for the
irradiated sample compared to the non-irradiated sample. Thus,
UV irradiation triggered a rapid release of 63% of the
encapsulated DxR (Supplementary Fig. 15a). In contrast, a non-
irradiated sample incubated at 37 °C released only about 20% of
the loaded DxR from motif 4 over 48 h of incubation, due to
thermal self-diffusion (Supplementary Fig. 15b). To compare the
UV-induced DxR release to thermally driven DxR diffusion at a
fixed time interval, aliquots of sample incubated at 37 °C for 48 h
were analyzed before and after irradiation with 365 nm UV light
for 5 min. The release of DxR was monitored by measuring the
fluorescence of irradiated vs. non-irradiated sample at 590 nm
using a fluorescence detector attached to HPLC. DxR-loaded
motif 4 incubated at 37 °C without UV exposure led to a release
of 20% of the loaded DxR within 48 h of incubation by thermal
self-diffusion. The same sample, however, released an additional
Table 1 Atto-labeled motifs 3 and 4 mixed in different ratios to form HyApNc nanoconstructs
Exp. no. Atto550-4 (µM) Atto647N-3 (µM) Volume (µL) Equivalents Atto550-4 I669a (mean± S.D.) I576b (mean± S.D.) I669/I576c
1 0.0 5.0 20 0.0 652± 206 41± 7 15.90
2 1.0 5.0 20 0.2 2317± 657 416± 116 5.56
3 1.75 5.0 20 0.35 5673± 881 775± 169 7.32
4 2.5 5.0 20 0.5 9604± 1172 1218± 234 7.88
5 5.0 5.0 20 1.0 21,098± 402 3553± 434 5.93
6 7.5 5.0 20 1.5 28,225± 1164 6106± 378 4.62
7 10 5.0 20 2.0 34,010± 3593 9992± 153 3.40
8 15 5.0 20 3.0 35,242± 5951 27,766± 4606 1.26
aFluorescence intensities at λ= 669 nm
bFluorescence intensities at λ= 576 nm
cEstimated ratio (I669/I576) from the FRET experiments
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50% of the loaded DxR immediately after UV irradiation
(Supplementary Fig. 15b, black square). These results support
the conclusion that the release of DxR from the motif 4 is
stimulated by UV irradiation.
Lipid-mediated self-assembly of motifs 3 and 4 forms HyApNc.
We next combined both lipid-modified motifs 3 and 4 to test
their lipid-mediated self-assembly into heterogeneous HyApNc.
By mixing free Atto-647N-trCLN3-L4 (Atto647N-3) with
Atto550-labeled DxR-L4 motif (Atto550-4) in different ratios,
hybrid nanoconstructs were formed and stabilized by the strong
hydrophobic interaction of the lipid tails. The Atto-dye labels
were attached at the 5′-end in immediate proximity to the lipid
modifications to ensure that intermolecular FRET effects report
the formation of micellar nanoconstructs. In the FRET experi-
ment nanoconstructs self-assembled by mixing a fixed con-
centration of 5 μM Atto647N-3 with Atto550-4 in concentrations
ranging between 1 and 15 μM (Table 1).
Fluorescence at λex = 535 nm (Fig. 4a) showed that the
nanoconstructs self-assembled with 0.2 equivalents of Atto550-4
(Atto647N-3:Atto550-4 = 5:1), yielding an intensity ratio
I669 × I576−1 of 5.56. In contrast, nanoconstructs self-assembled
with 0.35 or 0.5 excess equivalents of Atto550-4 showed an
increasing I669 × I576−1 value of 7.32 and 7.88, respectively, a
significant enhancement of ~32% and ~41% relative to the
Atto647N fluorescence. An increase in FRET observed with
increasing concentrations of Atto550-4 reached saturation
between 2.0 and 2.5 equivalents (Fig. 4b). Nevertheless the
I669 × I576−1 value already reaches 5.93 at one equivalent of Atto-
550-4 (Atto647N-3:Atto550-4 = 1:1). Therefore, we maintained
this ratio in the subsequent cellular studies to achieve a proper
balance between high target affinity (internalization efficiency)
and DxR carrying efficiency (cytotoxicity).
In a control experiment, we employed the Atto550-labeled
DxR-binding motif without lipid modification (a550-4w/oL4).
With this lipid-devoid motif, only diffusion-controlled encoun-
ters between Atto550 and Atto647N can occur, which should
result in very low relative intensities. Indeed, with a 1:1 ratio of
motif 3 and Atto550-4w/oL4 we observed an I669 × I576−1 value of
0.09, indicating that no hybrid micellar nanoconstructs are
forming (Fig. 4c). The FRET signal thus strictly depends on the
ratio of the two functional domains and on the presence of the L4
modification. A comparison of FRET efficiency values (Supple-
mentary Methods; Supplementary Fig. 16) suggested the 92%
FRET efficiency for assembled HyApNc consisting of motifs
Atto550-4 and Atto647N-3 as compared to 27% where both
motifs 4 and 3 lack the lipid modifications. When a non-cMet-
binding Atto647N-labeled mutant trCLN3-L4 motif (Atto647-
mut-3) was used instead of Atto647N-3, the resulting mutated
nanoconstruct HyApNc.mut yielded a FRET efficiency (97%)
similar to HyApNc. Together, these data provide evidence that
both motifs self-assemble to form hybrid heterogeneous nano-
constructs of spherical geometry when the lipid modifications are
present. The FRET signal intensity is also a good measure of
integrity of the nanoconstructs.
The resulting HyApNc consisting of 3 and 4 in a 1:1 ratio was
further analyzed by AFM to compare its size and structural
features with nanoconstructs resulting only from motif 3. We
observed that the hybrid micellar nanoconstruct retained its
spherical shape similar to the homogenous nanoconstructs
consisting of only motif 3 (Fig. 1c, f). However, their average
diameter is 32.3± 2.1 nm—larger than the homogenous nano-
constructs made from trCLN3-L4 (motif 3), which averaged 21.2
± 1.5 nm (Fig. 1d, g). This increase in size of the heterogenous
nanoconstructs as compared to the homogenous ones may result
from differences in the physico-chemical properties of the two
aptamers in 3 and 4, or from structural differences, or both.
For efficient cell internalization and for successful delivery of
the intercalated DxR, the integrity of the mixed micellar
nanoconstruts HyApNc, i.e., both motifs 3 and 4, must remain
intact as a single nanoconstruct and circulate in complex
biological media for a sufficiently long period of time. The
stability of the micelles as well as their circulation time is known
to be affected by the presence of serum proteins, which alter the
micellar equilibrium leading to their dissociation to varying
extents69,70. Therefore, we evaluated the integrity of HyApNc
upon interaction with HBS, and in presence of bovine serum
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albumin (BSA) at 37 °C over time (Supplementary Methods;
Supplementary Fig. 17a, b, c). We assessed the integrity of the
micellar nanoconstruct HyApNc by using the previously
assembled FRET pair (see Fig. 4) attached to the 5′-ends of both
motifs 3 (Atto647N-3) and 4 (Atto550-4). The intermolecular
FRET effect was monitored (Supplementary Fig. 17a, b) and an
increase in the fluorescence intensity at 576 nm and a decrease at
669 nm was observed over time. This result indicates that the
micellar nanoconstructs disintegrate gradually in the presence of
BSA or serum proteins contained in HBS. The FRET ratio =
I669 × (I669 + I576)−1 was calculated and plotted as a function of
time (Supplementary Fig. 17c). The HyApNc nanoconstructs
exhibited a half-life (t1/2) of 14 h in 95% HBS and of 18 h in 1 mM
BSA solution. The time-resolved emission data indicate that the
rate of micellar nanoconstruct disintegration in either BSA or
HBS was not significantly different. The t1/2 indicates an adequate
stability of the micelles in blood serum with slow disintegration
under our in vitro experimental conditions. It is possible that the
t1/2 of HyApNc will be further reduced in the blood stream
in vivo. However, if necessary for in vivo applications the half-life
of HyApNc could be further increased by elongating the lipid
chains and/or by using unsaturated lipids and crosslinking them
at the core of the nanostructures.
Uptake of aptameric nanoconstructs by cMet-expressing cells.
After confirming the successful fomation of the aptameric
nanoconstructs, the cell targeting ability and internalization effi-
cacy of aptamer trCLN3-L4 (3) mediated by cMet recognition
was investigated by using both confocal microscopy and flow
cytometry analysis. Cell uptake experiments were performed with
the NCI-H1838 lung cancer cell line that expresses cMet64. NCI-
H1838 cells incubated with different concentrations of the
Atto647N-3 (10 and 1 µM, respectively) at 37 °C for 90 min,
showed a strong and comparable intracellular red fluorescence at
both concentrations above the CMC value (Fig. 5a, b and Sup-
plementary Fig. 18a, b for 10 µM; Supplementary Fig. 18c, d for 1
µM). At 1 µM of Atto647N-3, a punctuated pattern of inter-
nalized nanostructures was observed in the cytoplasm, suggesting
that they may localize in endosomes (Supplementary Fig. 18c, d).
Indeed, the same experiment performed at 4 °C showed only a
weak membrane-localized fluorescence (Fig. 5c, d) with markedly
reduced Atto647N-fluorescence in the H1838 cells, consistent
with inhibition of endocytosis at low temperature71. When the
Atto647N-3 concentration was reduced to 0.2 µM, which is below
the CMC, a significantly weaker fluorescence signal was observed,
as expected (Supplementary Fig. 18e, f).
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cells treated with Atto647N-3 at 4 °C (red solid line), suggesting an endocytotic internalization pathway. A minimal shift in Atto647 fluorescence intensity
was observed for cells treated with either a scrambled aptamer Atto647N.mut-3 (blue solid line) or with Atto647N-trCLN3w/oL4 (black dotted line) at 37 °
C compared to untreated cells (gray shadow), indicating a marginal internalization presumably due to non-specific binding or lack of lipidation
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H1838 cells incubated with 5′-Atto647N-labeled double
mutant of 3 (Atto647N-mut 3) that does not bind to cMet
exhibited marginal cellular staining (Fig. 5e, f), consistent with
lack of internalization. Finally, the non-lipidated version of
Atto647N-trCLN3w/oL4 also showed low cellular staining (Fig. 5g,
h), suggesting that lipidation of the cMet-binding aptamer is
required for efficient uptake. This result may indicate that protein
target binding in solution could differ from targeting the protein
at the cell surface. Moreover, lipidation of aptamers potentially
improves their ability to target proteins expressed on cell surfaces
by self-organizing multiple aptamers in a single nanostructure,
although the generality of this notion remains to be demonstrated
with other aptamer/target systems.
These findings were further confirmed through flow cytometric
studies (Fig. 5i; Supplementary Methods). There was a noticeable
change in the fluorescence signal observed for cells treated with
free Atto647N-trCLN3w/oL4 (Fig. 5i, black dotted) compared to
the auto-fluorescence profile of untreated cells (Fig. 5i, gray area),
indicating low internalization. Compared to non-lipidated
Atto647N-trCLN3w/oL4, cells treated with Atto647N-3 at 37 °C
(Fig. 5i, green area) showed significantly higher shift in
fluorescence intensity. A minimal shift in fluorescence intensity
was also observed for cells treated with either Atto647N-mut 3
(Fig. 5i, blue curve) or Atto647N-3 at 4 °C (Fig. 5i, red curve) over
untreated cells (gray areas), indicating either a low non-specific
binding or only a membrane localized binding without
internalization at low temperature. Taken together, these results
show that important determinants for efficient uptake into H1838
cells are the ability to bind extracellular cMet by the aptamer
moieties, the ability to form nanoconstructs due to lipidation, and
that the uptake is temperature-dependent, supporting an
endocytotic mechanism.
We next performed cellular uptake studies of a dual-labeled
hybrid-nanoconstruct (HyApNc) containing a mixture of
Atto550-labeled 4 and Atto647N-labeled 3 motifs in a 1:1 ratio.
Both fluorescent probes constitute a suitable FRET pair entrapped
within the lipid core that can be employed to validate whether the
functional nanoconstructs enter and target H1838 cells. The
confocal images showed not only the cellular staining for both
dyes (Fig. 6a; c2: red, Fig. 6b; c3: magenta), but also a FRET signal
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Fig. 6 Cellular uptake of dual-labeled HyApNc consisting of A550-4 and A647N-3 motifs. a–c Confocal fluorescence images of H1838 cells treated with
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with HyApNc (e: A647N-3 + A550-4), and HyApNc.mut (f: A647N.mut-3 + A550-4) as a negative control with Atto647N-labeled mutant trCLN3.mut-L4
motif. The complete overlay sets for e and f are shown in Supplementary Fig. 19. Aptamer constructs were incubated at 37 °C for 2 h, followed by
membrane staining with Alexa488-WGA (green), and nuclei staining with Hoechst 33342 (blue). Scale bar: a–f 50 µm
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(Fig. 6c; c4: cyan) was observed. During confocal imaging all
settings were kept constant (for details, see Methods). To evaluate
the occurrence of FRET, we analyzed the images using a method
that was previously reported72, where the PixFRET plugin of the
image processing software ImageJ was used for FRET quantifica-
tion. Briefly, the bleed-through of the acceptor and donor
channels was determined and finally the calculated FRET images
were reconstructed (Fig. 6d; white: calculated FRET). The
calculated FRET images suggest donor and acceptor dyes are in
correct geometry, supporting the integrity of the nanoconstructs.
High FRET efficiencies were only observed when the designated
constructs were able to enter the cells (Fig. 6a–c). Figure 6e shows
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the overlay of the images shown in Fig. 6a–d (including nuclear
and membrane staining). In contrast, mutated nanoconstructs
(HyApNc.mut) containing the non-cMet-binding Atto647N-
labeled trCLN3.mut-L4 motif and Atto550-labeled motif 4
resulted in poor FRET efficiencies (Fig. 6f, Supplementary
Fig. 19f–j), similar to background signals, indicating that the
process of internalization is target-specific rather than occurring
randomly.
Photo-triggered release of DxR from HyApNc-DxR. After
successfully targeting the H1838 cells with HyApNc, we further
investigated the selective transport of DxR into the cells, followed
by its light triggered release from the HyApNc. The DxR-loaded
HyApNc (HyApNc–DxR complex) was prepared by mixing
motif 3 and 4 (1:1 ratio) with 10-fold excess of DxR followed by a
purification step using spin filtration (details are given in Meth-
ods). To ensure minimum cell mortality upon UV irradiation,
H1838 cells were irradiated at t = 0, 5, 10, 15, and 30 min,
respectively, at an intensity of 350 mW cm−2. Cell viability as a
function of time-dependent response to UV treatment was
measured by an MTT assay 24 h after irradiation. A maximum
survival rate comparable to the non-irradiated control (t = 0 min)
was observed at an irradiation time t ≤ 5 min (Supplementary
Fig. 20a, b).
To verify the HyApNc-mediated selective transport of DxR to
target cells and its light-triggered release from motif 4, we
monitored the fluorescence signal of DxR within and outside of
the cell nuclei that were treated with either free DxR (as control)
or with HyApNc-DxR (details of DxR loading: see Methods),
while keeping the DxR concentrations in the bound and the
unbound form fixed at 40 µM (5 μM HyApNc carrying eight
equivalents of DxR). The release of DxR from HyApNc was
investigated by confocal microscopy with and without subsequent
irradiation at 365 nm. Confocal images of the H1838 cells at 37 °C
after 2 h of incubation showed a decrease in the DxR fluorescence
signal in the cell nuclei in the following order: free DxR,
HyApNc–DxR complex with and without UV irradiation
(λ = 365 nm, 350 mW cm−2) (Fig. 7a–i). Strong DxR fluorescence
was observed in cell nuclei after treatment with free DxR,
indicating that free DxR readily diffuses through the plasma
membrane and accumulates almost exclusively in the nuclear
region (Fig. 7a–c). However, the HyApNc–DxR complex without
UV irradiation led to a considerably weaker DxR-fluorescence in
the nucleus and a noticeable fluorescence within the endoplasm
confirming that most of the DxR is predominantly localized
outside the nucleus bound to the HyApNc (Fig. 7d–f). In contrast,
when the HyApNc–DxR complex is exposed to irradiation
(λ = 365 nm, 350 mW cm−2) a discernible increase in both nuclear
and extranuclear fluorescence was detected (Fig. 7g–i). When
control experiments were performed with a construct lacking
DMAB (HyApNcw/oAz-DxR), near-identical DxR fluorescence
signals are predominantly observed in the cytosol of the cells with
and without UV exposure (Fig. 7j–o). No visible increase in the
DxR fluorescence signal was observed in either the nuclei or in
the cytosol when the cells treated with HyApNcw/oAz-DxR were
irradiated (Fig. 7m–o) compared to non-irradiated cells
(Fig. 7j–l).
To further validate these results, the HyApNc-mediated DxR
internalization with or without DMAB was evaluated by flow
cytometry. As a control, the DxR uptake of the non-targeted
mutated nanoconstruct HyApNc.mut-DxR was compared to that
of the targeted nanoconstructs HyApNc-DxR (Supplementary
Methods). To accomplish this, H1838 cells were incubated with
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free DxR, HyApNc.mut-DxR, HyApNc-DxR, or targeted nano-
constructs without DMAB (HyApNcw/oAz-DxR) at fixed DxR
concentrations of 8 μM either in its free form or in its complex
form with the carrier (1 µM of nanocarrier, each containing eight
equivalents of DxR). Treatment of cells with free DxR (orange
areas) induces a 5-fold increase in mean cellular fluorescence
intensity as compared to cells incubated with an equivalent dose
of either HyApNc-DxR (Fig. 7p, purple) or HyApNcw/oAz-DxR
(Fig. 7q, blue). Instead, irradiation of cells treated with HyApNc-
DxR (Fig. 7p, red dotted) induces only about a 1.3-fold shift in
the fluorescence intensity compared to the non-irradiated cells
(Fig. 7p, purple solid). This small shift in the fluorescence
intensity might be due to the limitations of the flow cytometer to
discriminate between the nuclear and the extranuclear fluores-
cence signal. In contrast, cells incubated with HyApNcw/oAz-DxR
showed a −1.05-fold shift in fluorescence intensity, and the FACS
profile of the irradiated sample (Fig. 7q, red dotted) was
comparable to the non-irradiated samples (Fig. 7q, blue solid).
Moreover, cells incubated with HyApNc-DxR exhibited a 2.8-fold
increase in the mean fluorescence signal compared to cells treated
with HyApNc.mut-DxR containing the same amount of DxR in
either case (Fig. 7p, purple vs. magenta). This result clearly
showed that non-targeted nanoconstructs HyApNc.mut-DxR
exhibited significantly lower efficacy in DxR delivery, consistent
with their lower level of cellular uptake compared to HyApNc-
DxR observed in Fig. 6. Overall this result indicates that after UV
irradiation, most of the intercalated DxR was released from
HyApNc having DMAB units and subsequently transferred into
the nuclei and colocalized with the Hoechst dye.
In vitro cytotoxicity of HyApNc-DxR against NCI-H1838 cells.
Having verified that the DxR can be selectively transported into
target cells, we evaluated the cytotoxicity of the free DxR, the
HyApNc-DxR, and the non-targeting HyApNc.mut-DxR nano-
constructs with and without UV irradiation in H1838 cells by an
MTT assay (for details, see Methods) in a dose-dependent way
between 0.125 and 50 µM (Fig. 8a). There was a clear dependence
of the H1838 cell viability on the concentration of DxR (Fig. 8a).
An IC50 of 11 µM (6.5 µg mL−1) was determined for HyApNc-
DxR irradiated with UV light (Fig. 8a, blue), and a similar level of
cytotoxicity (IC50 = 8 µM [4.7 µg mL−1]) was observed for free
DxR (Fig. 8a, red). However, no significant cytotoxicity was
measured when cells were either treated with HyApNc-DxR
without UV (Fig. 8a, black) or with HyApNc.mut-DxR (Fig. 8a,
green). Cells incubated with non-targeting HyApNc.mut-DxR
with subsequent UV irradiation under the same conditions
(Fig. 8a, green) exhibited about a 38% increase in cell survival
compared to cells treated with HyApNc-DxR at 8 µM loaded
DxR concentrations (green vs. blue), consistent with their lower
level of cellular uptake compared to HyApNc-DxR observed in
Fig. 6. This result suggests that the cMet-expressing H1838 cells
effectively internalized HyApNc-DxR due to receptor-mediated
endocytosis, while non-targeted nanoconstructs exhibited sig-
nificantly lower efficacy.
As an additional control, we conducted a time-dependent
cytotoxicity assay to determine whether DxR release would occur
solely through self-diffusion after endocytosis (i.e., no UV
radiation). To accomplish this, we used the DMAB lacking
construct (HyApNcw/oAz-DxR) at different incubation times.
H1838 cells were treated with unloaded HyApNc, HyApNc-DxR,
and HyApNcw/oAz-DxR for 2 h at 37 °C at 8 µM DxR dosage.
After 2 h post treatment, the cells were washed, the RPMI
medium replaced with fresh medium, and some of them (Fig. 8b,
dotted) were exposed to UV light for 5 min (λ = 365 nm; 350 mW
cm−2), while those that were not irradiated were used as controls
(Fig. 8b, solid). Afterward cells were further allowed to incubate at
37 °C for 8, 24, and 48 h, respectively, before being subjected to
the MTT assay. Cells treated with only RPMI medium and not
exposed to UV irradiation (Fig. 8b, gray solid) served as the
primary control.
Cells treated with HyApNc alone in combination with UV
irradiation exhibited similar survival rates as non-irradiated cells
treated with only RPMI medium (Fig. 8b, gray dotted vs. solid),
indicating that neither the nanoconstruct without DxR nor brief
UV exposure contribute significantly to cell death. In contrast, the
combination of HyApNc-DxR with UV irradiation induced an
approximately 2.8-fold decrease of cell viability compared to the
treatment with HyApNc-DxR alone (17 vs. 64%) 8 h post
treatment (Fig. 8b, red dotted vs. red solid). When cells were
treated with the photo-deactivated construct HyApNcw/oAz-DxR
in combination with UV light a 0.2-fold decrease of cell viability
compared to non-irradiated HyApNcw/oAz-DxR (49 vs. 59%) was
measured (Fig. 8b, blue dotted vs. blue solid). This result indicates
that the lower cell mortality is related to inefficient release of DxR
from the nanoconstrct without DMAB phtoswitches. We further
evaluated cell viability for the incubation times of 24 and 48 h
under similar conditions as for the 8 h incubation. Cells incubated
with HyApNc-DxR without UV irradiation (Fig. 8c, red solid)
showed a gradual decrease in viability from 64% (8 h) to 43% (24
h) to 21% (48 h). Cells incubated with HyApNcw/oAz-DxR under
the same conditions (Fig. 8c, blue solid) decreased from 59% (8 h)
to 44% (24 h) to 19% (48 h). When UV irradiation was applied to
the HyApNcw/oAz-DxR-treated cells (Fig. 8c, blue dotted), cell
viability was similar. Thus, a clear differentiation between 5 min
UV irradiation of HyApNc-DxR and all other conditions was
only seen for the 8 and 24 h incubation times, whereas at 48 h
incubation cells were killed equally efficient under all conditions
that contained DxR. At 48 h, a sufficient amount of intercalated
DxR might have diffused from the control-nanoconstructs or the
non-UV-irradiated ones spontaneously, and induce cell killing
equally efficiently. For UV-irradiated HyApNc-DxR, a ~80% cell
mortality is already achieved within a significantly shorter time
span of 8 h (Fig. 8c, red dotted).
Discussion
By exploiting aptamer-mediated selective cell targeting, photo-
induced structure switching, and lipid-mediated self-assembly, we
have developed a hybrid aptamer-nanoconstruct as a molecular
carrier system that allows selective transport of intercalated
cytotoxic drugs to target cells and release of the payload under
light irradiation. This design offers the possibility to self-assemble
multiple functional domains at once into a single nanoconstruct,
in our case the targeting ability of an anti-cMet aptamer, and an
intercalated drug-carrying motif, compared to the limited possi-
bility of introducing multiple functionalities into a single mod-
ified aptamer system through inherent synthetic efforts.
Fluorescence studies with pyrene loading showed that the self-
aggregated nanoconstructs were stabilized in aqueous solution
through hydrophobic interaction of the lipids. The mixed nature
of the nanoconstructs and their size was confirmed by FRET
studies and AFM measurements. Indeed, such self-assembled
structures even offer an unprecedented degree of control over the
ratio of different functional domains based on the therapeutic
requirements. Moreover, integrating multiple GC-rich hairpin-
duplex motifs affords several folds of loading of DxR into a single
nanoscaffold, thereby enhancing the payload capacity in com-
parison to a monomeric aptamer.
Confocal imaging and cell viability assays further demonstrated
a highly efficient cell uptake of the designed HyApNc into H1838
cells and an improved effect on tumor cell targeting by releasing
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DxR inside the cell by a light trigger. We do not mean to suggest
that UV light triggering will be compatible with therapy under
standard clinical practice, as the penetration depth of light is only
a few millimeters. While this skin depth may be sufficient for
some melanoma, a better choice would be azobenzene photo-
switches that isomerize with red light that has significantly higher
skin penetration depth73. Alternatively, fiber optic endoscopy
might direct UV light to potential tumor sites deeper inside the
body.
An important outcome of our study is that lipidation of the
aptamer motifs leads to a stable nanoconstruct with high resis-
tance against nucleases accompanied by a drastically improved
cell uptake compared to the unmodified aptamer. Despite using
UV light as a trigger for unloading DxR, the induced cell death
was successful without killing the cell itself by irradiation. As
such, the successful implementation of DMAB into a photo-
responsive DNA motif to control the drug release in cells using
UV light represents a significant step toward aptamer-based
targeted therapeutics. On the other hand, the possible risks
associated with UV light such as cellular damage and stability of
biological systems can be avoided by using low-intensity irra-
diation for a short period of time as indicated by our experiments.
This concept might be further limited when applying it in vivo
where the significant systemic dilution of the nanoconstructs
could disintegrate the micelles more rapidly below the CMC. A
possible solution to this issue might be attaching longer lipid tails
to the ODN motifs, or using unsaturated lipids and cross-linking
them inside the lipid core.
Ultimately, our work addresses fundamental obstacles related
to aptamer-mediated tumor targeting while designing a multi-
functional nanoconstruct with improved nuclease stability, high
target-binding affinity, and increased tumor uptake, essential
prerequisites for next-generation aptamer-based targeted ther-
apeutics. Taken together, all these combined features make this
platform widely applicable for the simultaneous delivery of a
variety of different regulatory molecules, such as AntagomiRs,
small interfering RNAs, microRNAs, drugs, and other molecules
with high specificity and efficiency to specifically block functions
of disease-relevant biomolecules.
Methods
Materials. All chemicals including DxR were purchased from Sigma-Aldrich
unless otherwise specified and were used as received. cMet-Fc, which represents the
ectodomain of cMet fused to the Fc domain of human IgG1, was purchased from
R&D Systems. Wheat Germ Agglutinin, Alexa Fluor® 488 Conjugate, and Hoechst
33342 were purchased from Life Technologies (Grand Island, NY, USA). γ-32P-
labeled ATP (250 μCi) was purchased from PerkinElmer Health Science B. V., The
Netherlands. T4 Polynucleotide kinase and 1 × polynucleotide buffer were obtained
from New England Biolabs, Frankfurt a. M., Germany. Binding buffer used for the
aptamer competition-binding assay was prepared by adding E. coli tRNA (Roche
AG, Mannheim, Germany), BSA (Thermo Fischer Scientific) into Dulbeccos PBS
(Gibco, Life Technologies).
All solvents, reagents, and building blocks for oligonucleotide synthesis were
obtained from Proligo, Hamburg, Germany. The anti-cMet aptamer motif
(trCLN3) and its lipid derivatives (trCLN3-L4 and trCLN3.mut-L4) were
synthesized according to the phosphoramidite protocol using an ABI
3400 synthesizer (Applied Biosystems). DxR-carrying DxR-L4 modified with
DMAB and C12-lipid tails as well as the fluorescent-labeled (Atto647N-, Atto550-,
and 6FAM) trCLN3-L4 and DxR-L4 motifs were purchased in HPLC purified form
from Ella Biotech GmbH, Munich, Germany.
Cell culture and confocal microscopy. The human NSCLC cell line H1838 was
obtained from the American Type Culture Collection (ATCC). Cell cultures were
tested for mycoplasma contamination by using the PCR-based Venor®GeM
Mycoplasma detection kit. Cells were grown in T-75 cm2 flasks using RPMI 1640
(Invitrogen) supplemented with 10% FCS in a humidified atmosphere at 37 °C and
5% CO2. Cell lines were subcultured twice a week at a ratio of 1:4 depending on the
confluence and cell density was determined with a hemocytometer before each
experiment. Cells were detached using 1 mL Trypsin-EDTA solution (Sigma-
Aldrich) followed by neutralization with 25 mL of RPMI medium and the cells
were collected by centrifugation for 5 min at 400 rpm.
In vitro cell imaging of the cell internalization studies were performed using
fluorescence microscopy. Prior to each experiment one 70–80% confluent flask was
trypsinized and suspended with 10 mL of cell medium. 10 µL of the cell solution
was pipetted onto a haemocytometer and the cells were counted. Twenty-four
hours prior to the internalization experiments approximately 10,000 NSCLC cells
were seeded in 96-well glass bottom multiwell cell culture plates (MatTek®
Corporation). The plates were then incubated for 24 h at 37 °C in 5% CO2
atmosphere. After 24 h of incubation the cells were first washed with 1× PBS buffer
and incubated with various labeled aptameric nanoconstruts (trCLN3-L4, trCLN3.
mut-L4, HyApNc-DxR, HyApNc.mut-DxR, or free DxR) in 100 µL of RPMI 1640
with 10% FCS medium containing 1 mM MgCl2 at 37 and 4 °C separately for 2 h.
The final concentrations of the labeled micelles were fixed at 10 μM. Afterward,
cells were washed with fresh medium and Dulbeccos 1× PBS followed by 10 min
fixation with 200 µL of a 3.7% (w/v) paraformaldehyde solution in Dulbeccos 1×
PBS. Fixed cells were washed with fresh medium and Dulbeccos 1× PBS followed
by staining with 200 µL of nuclear and plasma membrane staining reagent [60 µL
(1 mgmL−1) of Alexa Fluor 488-WGA and 20 µL of Hoechst 33342 (1 mM) in 4.0
mL in 1× PBS buffer] and incubated for 10 min at 37 °C. After 10 min, the labeling
solutions were removed and the stained cells were washed with 1× PBS (2 × 200 µL)
followed by addition of 200 µL of 1× PBS buffer. Finally, the 96-well plate was
mounted with a multi-well plate holder and the confocal imaging of the fixed cells
was performed by using a NikonTi-E Eclipse inverted confocal laser-scanning
microscope equipped with a 60× Plan Apo VC Oil-immersion DIC N2 objective, a
Nikon C2 plus confocal laser scan head and a pinhole of 1.2 airy unit (30 μm). The
laser scanning Nikon Confocal Workstation with Galvano scanner, and lasers 408,
488, 561, and 637 nm was used, attached to a Nikon Eclipse Ti inverted
microscope. Images were captured in 1024 × 1024 pixels format using NIS-
Elements software (Nikon Corporation) and the raw images were processed using
ImageJ software. The standardized optical setups of imaging, pin-holes, objective,
laser power, and photomultiplier gain were kept constant while recording the data
for all measurements.
The identity of the cell line was verified based on microsatellite genotyping by
the ECACC Cell Line Identity Verification Service. The STR profiles matched the
profiles of the cell lines as deposited in the ATCC and ECACC STR databases.
Atomic force microscopy. All AFM images of the trCLN3-L4 and HyApNc
aggregates were taken by using a Nanowizard III AFM (JPK Instruments, Berlin) in
tapping mode. ACTA probes with silicon tips were used for imaging in dry mode
in air. A volume of 3 µL (5 mM) of a solution of magnesium acetate in water was
deposited on a freshly cleaved mica surface layer and allowed to incubate for 3 min
and afterward the surface was rinsed with 2 × 10 µL of milli-Q water and dried
under air pressure. For imaging a volume of 3 µL of the trCLN3-L4/HyApNc
solutions in ultra pure water were spotted on the pre-treated mica surface and
allowed to incubate for 1 min. After an incubation time of 1 min on the mica
surface the excess sample solution was gently shaken off and the mica surface was
blown dry with air pressure and mounted to the AFM microscope for immediate
imaging. The raw AFM data were processed using the JPK processing software.
TEM analysis. The size and structure of the trCLN3-L4 nanoconstructs were
analyzed by negative stain electron microscopy. Samples were prepared using
negative staining74. In brief, carbon coated grids (Quantifoil Micro Tools GmbH,
Jena, Germany, 200 mesh) were glow discharged to render the surface hydrophilic
prior to applying samples. 10 µL of an aqueous solution of trCLN3-L4 were applied
to the grid. Afterward excess solution was carefully blotted off using filter paper
followed by three times washing with ddH2O. In the final step, grids were stained
with negative staining reagent by placing them (plastic side down) on a 10 µL drop
of freshly prepared 2% (v/v) uranyl formiate aqueous staining solution. TEM
micrographs were recorded using a JEOL JEM 2200 FS electron microscope (JEOL,
Japan) operated at 200 kV. The size of the micelles measured on the TEM images
could typically be observed in a range between 20 and 25 nm.
ESI mass spectrometry. Molecular weights of the trCLN3-L4 and DxR-L4 motifs
were analyzed by ESI-LCMS in negative ion mode using a Bruker Esquire HCT
6000 ion-trap MS system with an electrospray ionization source in line with an
Agilent 1100 series HPLC system with a ZORBAX SB-18 analytical column (2.1 ×
50 mm). An elution buffer (10 mM TEA + 100 mM HFIP) in combination with
linear gradients of acetonitrile from 0 to 80% in 30 min was used as mobile phase
for analysis. The m/z ratio is calculated by deconvolution of the ionic fragments
using Bruker Compass Data Analysis Software.
Serum stability of lipidated and non-lipidated trCLN3 derivatives. Serum
stabilities of trCLN3, its two point mutant non-binding variant trCLN3.mut, and
their corresponding lipid-functionalized derivatives trCLN3-L4 and trCLN3.mut-
L4 were investigated in FCS and HBS. For this purpose, the aptamer motifs
were labeled at their 5′-end with 32P to form radiolabeled oligonucleotides. The
degradation tests of all the aptamer motifs were performed for 0–72 h at 37 °C. 6
pmol (12 µL of 0.5 μM) of the radio-labeled aptamer (5′-end-labeled with γ-32P)
was incubated in a volume of 300 µL freshly thawed PBS-buffered FCS or HBS
(270 µL serum + 30 µL 10 × PBS). For each measurement 10 µL of the samples were
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removed, mixed with 90 µL of gel loading buffer (80% formamide + 5 mM EDTA +
0.01% SDS) and subsequently stored at −20 °C. Aliquots of samples were taken
after indicated time intervals of 0, 0.3, 1.5, 3, 6, 24, 48, 60, and 72 h, respectively.
The serum stability of the aptamer in FCS or in HBS at different time intervals were
analyzed on a denaturing PAGE by loading 10 µL of each sample onto a 10% TAE-
Urea gel and running the gels for 90 min at 350 V. Gels were wrapped in clingfilm
and exposed to a phosphorimager screen in a closed cassette over a period of 12 h
and finally the residual intact aptamer bands were analyzed by scanning the screen
in a phosphorimage-scanner (FujiFilm FLA 3000). Intensities of the residual intact
aptamer bands were calculated applying AIDA image analyzer software program.
Serums half-lives of the selected aptamers were determined by using a half-life
curve-fitting data analysis program (GraphPad Prism).
Assembly of trCLN3-L4 and HyApNc nanoconstructs. The assembly of both the
homogeneous nanoconstructs and hybrid micellar nanoconstructs (HyApNc) in
aqueous solution, induced by microphase separation, with an outer shell of apta-
meric DNA and an inner core of the hydrophobic lipids was performed by
employing a simple heating and cooling procedure. An aqueous solution of 250
pmol of trCLN3-L4 was added to 250 pmol of DxR-L4 motif dissolved in a volume
of 50 µL milli-Q H2O (10 μM solution). The resulting solution was heated to 90 °C
for 10 min and subsequently cooled down to a temperature of 10 °C at a rate of 1 °C
per 10 min. In case of the aptamers functionalized with fluorescent markers, the
solutions were heated up to 70 °C instead of 90 °C and then gradually cooled down
to a temperature of 10 °C at a rate of 1 °C per 10 min using a thermocycler.
Loading HyApNc carrier with DxR. DxR-loaded hybrid-aptameric nanoconstruct
(HyApNc-DxR) was prepared by mixing trCLN3-L4 3 with DxR-L4 4 motif in 1:1
ratio with a 10-fold excess of DxR in binding buffer (1× PBS + 1 mM MgCl2). The
solution was incubated at 90 °C for 10 min and slowly cooled down to room
temperature overnight at a rate of 1 °C per 10 min in order to intercalate DxR into
the DxR-L4 motif. The DxR-loaded HyApNc was transferred to an Ami-
conⓇ Ultra-0.5 centrifugal filter column with 3 K molecular weight cutoff and
excess of free DxR which is not intercalated into DxR-L4 motif was removed by
three times consecutive centrifugation at 14,000 × g for 10 min at room tempera-
ture while adding fresh binding buffer at each centrifugation step. After each
centrifugation step, a UV/vis spectrum of the flow through washing was recorded
and a reduction in DxR absorbance further confirmed the successive removal of
excess DxR through repeated washing.
Cell viability assay. To assess the cytotoxicity of free DxR and HyApNc-DxR in
NCI-H1838 lung cancer cells, first the H1838 cells (2 × 104 cells per well) were
seeded in a 96-well plate and grown for 24 h. The cells were then washed with 1×
PBS (200 µL) and subsequently treated with free DxR (as control), HyApNc-DxR,
or HyApNc.mut-DxR in a dose-dependent way with a final DxR concentration
ranging from 0.125 to 50 µM per well. After 2 h post treatment, the cells were
washed; the RPMI medium was replaced with a fresh RPMI medium, and subse-
quently either irradiated with UV light for 5 min (λ = 365 nm; 350 mW cm−2), or
not irradiated. Afterward the cells were incubated for another 24 h at 37 °C.
For time-dependent cytotoxicity assays, cells were grown at different seeding
densities of 10,000, 15,000, 20,000, and 30,000 cells/well in a 96-well plate for 24 h.
The cells were then washed with 1× PBS and subsequently incubated with
unloaded HyApNc, HyApNc-DxR, and HyApNpw/oAz-DxR, respectively, with a
final DxR concentration of 8 μM in the culture medium. After 2 h post treatment,
the cells were washed; the RPMI medium was replaced with fresh RPMI medium,
and subsequently either irradiated with UV light for 5 min (λ = 365 nm; 350 mW
cm−2), or not irradiated. Then the cells are allowed to culture for another 8, 24, or
48 h, respectively.
Then for both experiments, 15 µL of an MTT stock solution (5 mgmL−1) was
added to each well and the cells were incubated at 37 °C for 6 h. After 6 h post
treatment with MTT solutions, 100 µL of the SDS-HCL solution was added to each
well and mixed thoroughly with a pipette and incubated at 37 °C for an additional
12 h. Finally, the absorbance was measured at λ = 570 nm by using a Tecan Infinite®
M1000 PRO microplate reader.
Data availability. The data sets within the article and supplementary files gener-
ated during the current study are available from the authors upon request.
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